205 related articles for article (PubMed ID: 24025152)
21. ECM1 and KRT6A are involved in tumor progression and chemoresistance in the effect of dexamethasone on pancreatic cancer.
Shinomiya Y; Kouchi Y; Harada-Kagitani S; Ishige T; Takano S; Ohtsuka M; Ikeda JI; Kishimoto T
Cancer Sci; 2024 Jun; 115(6):1948-1963. PubMed ID: 38613239
[TBL] [Abstract][Full Text] [Related]
22. Identification of inhibitors synergizing gemcitabine sensitivity in the squamous subtype of pancreatic ductal adenocarcinoma (PDAC).
Er JL; Goh PN; Lee CY; Tan YJ; Hii LW; Mai CW; Chung FF; Leong CO
Apoptosis; 2018 Jun; 23(5-6):343-355. PubMed ID: 29740790
[TBL] [Abstract][Full Text] [Related]
23. pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant K-Ras-addicted pancreatic cancer cells and mouse model.
Dutta D; Ray P; De A; Ghosh A; Hazra RS; Ghosh P; Banerjee S; Diaz FJ; Upadhyay SP; Quadir M; Banerjee SK
PLoS One; 2024; 19(4):e0297749. PubMed ID: 38687749
[TBL] [Abstract][Full Text] [Related]
24. Co-delivery of autophagy inhibitor and gemcitabine using a pH-activatable core-shell nanobomb inhibits pancreatic cancer progression and metastasis.
Chen X; Tao Y; He M; Deng M; Guo R; Sheng Q; Wang X; Ren K; Li T; He X; Zang S; Zhang Z; Li M; He Q
Theranostics; 2021; 11(18):8692-8705. PubMed ID: 34522207
[No Abstract] [Full Text] [Related]
25. Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer.
Dash S; Ueda T; Komuro A; Honda M; Sugisawa R; Okada H
Cell Death Dis; 2024 Feb; 15(2):131. PubMed ID: 38346958
[TBL] [Abstract][Full Text] [Related]
26. Examination of Wnt signaling as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC) using a pancreatic tumor organoid library (PTOL).
Hawkins HJ; Yacob BW; Brown ME; Goldstein BR; Arcaroli JJ; Bagby SM; Hartman SJ; Macbeth M; Goodspeed A; Danhorn T; Lentz RW; Lieu CH; Leal AD; Messersmith WA; Dempsey PJ; Pitts TM
PLoS One; 2024; 19(4):e0298808. PubMed ID: 38598488
[TBL] [Abstract][Full Text] [Related]
27. Identification of laminin γ2 as a prognostic and predictive biomarker for determining response to gemcitabine-based therapy in pancreatic ductal adenocarcinoma.
Okada Y; Nishiwada S; Yamamura K; Sho M; Baba H; Takayama T; Goel A
Eur J Cancer; 2021 Mar; 146():125-134. PubMed ID: 33607476
[TBL] [Abstract][Full Text] [Related]
28. The ATR Inhibitor AZD6738 Synergizes with Gemcitabine
Wallez Y; Dunlop CR; Johnson TI; Koh SB; Fornari C; Yates JWT; Bernaldo de Quirós Fernández S; Lau A; Richards FM; Jodrell DI
Mol Cancer Ther; 2018 Aug; 17(8):1670-1682. PubMed ID: 29891488
[TBL] [Abstract][Full Text] [Related]
29. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells.
Avan A; Crea F; Paolicchi E; Funel N; Galvani E; Marquez VE; Honeywell RJ; Danesi R; Peters GJ; Giovannetti E
Mol Cancer Ther; 2012 Aug; 11(8):1735-46. PubMed ID: 22622284
[TBL] [Abstract][Full Text] [Related]
30. Gemcitabine-Induced TIMP1 Attenuates Therapy Response and Promotes Tumor Growth and Liver Metastasis in Pancreatic Cancer.
D'Costa Z; Jones K; Azad A; van Stiphout R; Lim SY; Gomes AL; Kinchesh P; Smart SC; Gillies McKenna W; Buffa FM; Sansom OJ; Muschel RJ; O'Neill E; Fokas E
Cancer Res; 2017 Nov; 77(21):5952-5962. PubMed ID: 28765154
[TBL] [Abstract][Full Text] [Related]
31. Extracellular lumican inhibits pancreatic cancer cell growth and is associated with prolonged survival after surgery.
Li X; Truty MA; Kang Y; Chopin-Laly X; Zhang R; Roife D; Chatterjee D; Lin E; Thomas RM; Wang H; Katz MH; Fleming JB
Clin Cancer Res; 2014 Dec; 20(24):6529-40. PubMed ID: 25336691
[TBL] [Abstract][Full Text] [Related]
32. Combined blockade of TGf-β1 and GM-CSF improves chemotherapeutic effects for pancreatic cancer by modulating tumor microenvironment.
Liu Q; Wu H; Li Y; Zhang R; Kleeff J; Zhang X; Cui M; Liu J; Li T; Gao J; Pan B; Wu W; Wang W; Zhou L; Guo J; Dai M; Zhang T; Liao Q; Lu Z; Zhao Y
Cancer Immunol Immunother; 2020 Aug; 69(8):1477-1492. PubMed ID: 32285172
[TBL] [Abstract][Full Text] [Related]
33. PTBP3 promotes malignancy and hypoxia-induced chemoresistance in pancreatic cancer cells by ATG12 up-regulation.
Ma J; Weng L; Jia Y; Liu B; Wu S; Xue L; Yin X; Mao A; Wang Z; Shang M
J Cell Mol Med; 2020 Mar; 24(5):2917-2930. PubMed ID: 31989778
[TBL] [Abstract][Full Text] [Related]
34. The rescue of miR-148a expression in pancreatic cancer: an inappropriate therapeutic tool.
Delpu Y; Lulka H; Sicard F; Saint-Laurent N; Lopez F; Hanoun N; Buscail L; Cordelier P; Torrisani J
PLoS One; 2013; 8(1):e55513. PubMed ID: 23383211
[TBL] [Abstract][Full Text] [Related]
35. Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages.
Beatty GL; Winograd R; Evans RA; Long KB; Luque SL; Lee JW; Clendenin C; Gladney WL; Knoblock DM; Guirnalda PD; Vonderheide RH
Gastroenterology; 2015 Jul; 149(1):201-10. PubMed ID: 25888329
[TBL] [Abstract][Full Text] [Related]
36. Modulation of Cancer-Associated Fibrotic Stroma by An Integrin α
Turaga RC; Sharma M; Mishra F; Krasinskas A; Yuan Y; Yang JJ; Wang S; Liu C; Li S; Liu ZR
Cell Mol Gastroenterol Hepatol; 2021; 11(1):161-179. PubMed ID: 32810598
[TBL] [Abstract][Full Text] [Related]
37. CHES1 modulated tumorigenesis and senescence of pancreas cancer cells through repressing AKR1B10.
Kong D; Wu Y; Tong B; Liang Y; Xu F; Chi X; Ni L; Tian G; Zhang G; Xu Z
Biochim Biophys Acta Mol Basis Dis; 2024 Aug; 1870(6):167214. PubMed ID: 38718846
[TBL] [Abstract][Full Text] [Related]
38. HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma.
Liau SS; Whang E
Clin Cancer Res; 2008 Mar; 14(5):1470-7. PubMed ID: 18316571
[TBL] [Abstract][Full Text] [Related]
39. K-ras oncogene silencing strategy reduces tumor growth and enhances gemcitabine chemotherapy efficacy for pancreatic cancer treatment.
Réjiba S; Wack S; Aprahamian M; Hajri A
Cancer Sci; 2007 Jul; 98(7):1128-36. PubMed ID: 17489984
[TBL] [Abstract][Full Text] [Related]
40. Bisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound paclitaxel in pancreatic ductal adenocarcinoma.
Gonzalez-Villasana V; Rodriguez-Aguayo C; Arumugam T; Cruz-Monserrate Z; Fuentes-Mattei E; Deng D; Hwang RF; Wang H; Ivan C; Garza RJ; Cohen E; Gao H; Armaiz-Pena GN; Del C Monroig-Bosque P; Philip B; Rashed MH; Aslan B; Erdogan MA; Gutierrez-Puente Y; Ozpolat B; Reuben JM; Sood AK; Logsdon C; Lopez-Berestein G
Mol Cancer Ther; 2014 Nov; 13(11):2583-94. PubMed ID: 25193509
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
